597 related articles for article (PubMed ID: 22562782)
1. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
[TBL] [Abstract][Full Text] [Related]
2. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
Hsu TY; Chirovsky D; Moy FM; Ambegaonkar BM
Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
[TBL] [Abstract][Full Text] [Related]
3. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
4. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
Khovidhunkit W; Silaruks S; Chaithiraphan V; Ongphiphadhanakul B; Sritara P; Nimitphong H; Benjanuwattra T; Ambegaonkar BM
Angiology; 2012 Oct; 63(7):528-34. PubMed ID: 22222187
[TBL] [Abstract][Full Text] [Related]
7. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
8. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
Bersot TP; Pépin GM; Mahley RW
Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
[TBL] [Abstract][Full Text] [Related]
9. Role of lipid and lipoprotein profiles in risk assessment and therapy.
Ballantyne CM; Hoogeveen RC
Am Heart J; 2003 Aug; 146(2):227-33. PubMed ID: 12891189
[TBL] [Abstract][Full Text] [Related]
10. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
11. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
[TBL] [Abstract][Full Text] [Related]
12. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
14. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
16. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.
Mosca L; Merz NB; Blumenthal RS; Cziraky MJ; Fabunmi RP; Sarawate C; Watson KE; Willey VJ; Stanek EJ
Circulation; 2005 Feb; 111(4):488-93. PubMed ID: 15687138
[TBL] [Abstract][Full Text] [Related]
17. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
18. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
[TBL] [Abstract][Full Text] [Related]
20. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]